MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular™, a newly formed company affiliated with RenalGuard Solutions™, is a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF). RenalGuard also announced the completion of a $7 million financing provided by strong support from existing investors and Abiomed, Inc. as a participant and […]
Tag: RenalGuard
RenalGuard Solutions Reaches Milestone of 20,000 Patients Treated with RenalGuard
MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced the treatment of 20,000 patients with RenalGuard® for the prevention of Contrast-Induced Nephropathy (CIN). Contrast-Induced Nephropathy is a form of acute kidney injury (AKI) that affects 10 to 20 percent of patients undergoing […]
New Study Demonstrates Feasibility of Using RenalGuard-Guided Diuretic Therapy for Acute Heart Failure Patients
MILFORD, Mass. & VIENNA–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced new clinical study results demonstrating the feasibility of using RenalGuard®-Guided Diuretic Therapy to optimize fluid management in Acute Decompensated Heart Failure (ADHF) patients while alleviating related symptoms. Study results were […]
RenalGuard Solutions Announces Late Breaking Clinical Trial Data Accepted for Presentation at Heart Failure 2018
MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced that new data from a clinical trial studying RenalGuard®-Guided Diuretic Therapy will be presented as a late breaking abstract at Heart Failure 2018, the annual meeting of the Heart Failure Association of […]
RenalGuard Solutions Announces Appointment of Dr. Howard R. Levin as Chief Medical Officer
MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that Howard R. Levin, M.D., has been named the company’s chief medical officer. A veteran in the field of biomedical engineering and cardiology and one of the original developers of RenalGuard Therapy®, Dr. Levin […]
RenalGuard System Demonstrates Promising Results from First-in-Man Studies to Evaluate Technology for Heart Failure Patients
MILFORD, Mass.–(BUSINESS WIRE)– RenalGuard Solutions, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today reported positive results from a first-in-man feasibility study focusing on a novel use of the RenalGuard System® to manage fluids during diuretic therapy in congestive heart failure patients suffering from fluid overload. The results were recently […]
Meta-Analysis Shows RenalGuard(R) Offers Dramatic Benefit for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Cardiovascular Interventions
MILFORD, MA–(Marketwired – September 13, 2017) – A new meta-analysis suggests that the use of the RenalGuard System® reduces the rate of contrast-induced acute kidney injury (CI-AKI) compared to standard intravascular volume expansion in moderate-to-high-risk patients with chronic kidney disease who are undergoing cardiac interventional procedures. The study, published in the Journal of Interventional Cardiology, also found […]
RenalGuard Names Former St. Jude Medical (STJ)-Abiomed (ABMD) Exec as New CEO
MILFORD, MA–(Marketwired – July 10, 2017) – RenalGuard Solutions, Inc. today announced the appointment of Jim Dillon, former St. Jude Medical and Abiomed commercial executive, as Chief Executive Officer. “Jim joins RenalGuard with a proven record of executive leadership related to innovative medical devices that serve the needs of the interventional cardiology, heart failure and cardiac […]
Recent
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
Popular
- No commented posts yet